display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all populationmNSCLC - L1 - PDL1 negativemNSCLC - L1 - PDL1 positivemNSCLC - L1 - TMB>10Mbnon squamous - mNSCLC - L1 - all populationnon squamous - mNSCLC - L1 - Wild Type (WT)squamous - mNSCLC - L1 - all population
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC CA184-104
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMpower-110 ... IMpower-110 ... IMpower-110 ...
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel IMpower-150 ... IMpower-150 ... IMpower-150 ...
atezolizumab plus carboplatin plus nab-paclitaxel IMpower-130 ... IMpower-130 ... IMpower-131 ...
atezolizumab plus carboplatin plus paclitaxel IMpower-150 ... IMpower-131 ...
atezolizumab plus pemetrexed and platin IMpower-132 ...
cemiplimab EMPOWER lung1 ... EMPOWER lung1 ...
durvalumab based treatment
durvalumab alone MYSTIC ... MYSTIC ...
nivolumab based treatment
nivolumab alone CheckMate 026 ... CheckMate 026 ...
nivolumab plus SoC CheckMate 227 ...
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-024 ... KEYNOTE-042 ... KEYNOTE-042 ... KEYNOTE-042 ...
pembrolizumab and pemetrexed plus platin KEYNOTE-021
pembrolizumab plus SoC KEYNOTE-189 KEYNOTE-407
sintilimab based treatment
sintillimab plus SoC ORIENT-11
Immune checkpoint association
durvalumab plus tremelimumab MYSTIC ... MYSTIC ...
nivolumab plus ipilimumab CheckMate 227 ... CheckMate 227 ...
nivolumab plus ipilimumab plus SoC CheckMate 9LA
pembrolizumab plus ipilimumab KEYNOTE-598

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons